Aspire Biopharma Holdings, Inc.
ASBP
$8.87
-$0.38-4.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 97.70K | 34.60K | 6.20K | 1.90K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.70K | 34.60K | 6.20K | 1.90K | -- |
| Cost of Revenue | 122.20K | 29.00K | 6.40K | 1.10K | -- |
| Gross Profit | -24.40K | 5.70K | -100.00 | 900.00 | -- |
| SG&A Expenses | 6.21M | 4.48M | 4.30M | 3.10M | 2.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.17M | 5.46M | 5.23M | 4.04M | 3.11M |
| Operating Income | -7.08M | -5.43M | -5.22M | -4.04M | -3.11M |
| Income Before Tax | -11.05M | -11.76M | -24.48M | -20.54M | -18.90M |
| Income Tax Expenses | -- | -- | -- | 0.00 | 1.00K |
| Earnings from Continuing Operations | -11.05 | -11.76 | -24.48 | -20.54 | -18.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.05M | -11.76M | -24.48M | -20.54M | -18.90M |
| EBIT | -7.08M | -5.43M | -5.22M | -4.04M | -3.11M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -121.90 | -168.87 | -653.17 | -631.19 | -595.76 |
| Normalized Basic EPS | -75.86 | -99.00 | -122.98 | -109.24 | -87.07 |
| EPS Diluted | -121.90 | -168.87 | -653.17 | -631.19 | -595.76 |
| Normalized Diluted EPS | -75.86 | -99.00 | -122.98 | -109.24 | -87.07 |
| Average Basic Shares Outstanding | 1.32M | 324.30K | 199.20K | 137.00K | 118.70K |
| Average Diluted Shares Outstanding | 1.32M | 324.30K | 199.20K | 137.00K | 118.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |